Prior authorization (PA) is the step where your insurer decides whether it will pay for a GLP-1 before the pharmacy can fill it. Your prescriber submits clinical documentation; the plan compares it to its own written coverage criteria and approves or denies. Approval usually turns on a BMI threshold, a weight-related condition, evidence of prior lifestyle attempts, and sometimes a cheaper drug tried first. Denial is common — and denials can be appealed.
This page is about the paperwork, not the pharmacology. If you want the drugs themselves explained, start with GLP-1 medications explained. If you're weighing which one, see Zepbound vs Wegovy.
What prior authorization actually is (and why it exists)
A PA is a rationing mechanism. That is not a slur — it is the honest description. Plans use it when a drug is expensive, widely wanted, and prescribed for a condition where the plan believes some prescriptions are outside the label or outside what it agreed to cover. GLP-1s for weight are the single clearest example in the American market right now: high list prices, enormous demand, and an indication that a great many members meet.
So the plan writes a criteria document — sometimes called a coverage policy, medical policy, or utilization-management criterion — and pays only for requests that match it. Your prescriber's clinical judgment is not the deciding vote. The document is.
Which means the whole game is: get the document, then show — truthfully — where your chart already meets it.
What plans typically ask for
Criteria vary by plan and are rewritten often, so treat the table below as the shape of the ask, not as your plan's rules. Nobody outside your plan can tell you your plan's rules.
| Requirement | What it usually looks like | What proves it |
|---|---|---|
| BMI threshold | BMI 30 or higher; or BMI 27 or higher with a weight-related condition. This mirrors the FDA-approved label language for Wegovy. | Recent charted height/weight — often within the last 3–6 months, sometimes a baseline from before any treatment. |
| Weight-related comorbidity (if BMI 27–29.9) | Hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, prediabetes, or similar — the exact accepted list is plan-specific. | An active coded diagnosis in the chart, plus supporting labs, a BP log, or a sleep study. |
| Documented lifestyle attempt | Frequently phrased as a period (commonly around three to six months) of a structured diet and activity program without adequate result. | Visit notes describing the plan, a dietitian referral, program records, weight trend over time. |
| Step therapy | Some plans require trying an older or cheaper agent first, or require the plan's preferred GLP-1 brand rather than the one prescribed. | Pharmacy fill history, or documentation of intolerance/contraindication to the preferred agent. |
| Ongoing-benefit re-authorization | Approval is usually time-limited (often 6–12 months) and renewal often requires documented weight loss on therapy. | Serial weights in the chart. Miss the re-auth and the pharmacy stops filling. |
Two things to notice. First, the criteria are frequently chart requirements, not you requirements — you may already qualify, and the note simply doesn't say so. Second, the re-authorization clause is the one people never see coming: coverage that starts is not coverage that continues.
The three things you can actually do
1. Get the plan's criteria in writing — you are entitled to ask
Call the member number on your card and ask: "Please send me the prior-authorization coverage criteria for GLP-1 medications for weight management under my plan, and the PA form my prescriber must submit." Most plans publish these as PDFs; ask for the link or a mailed copy.
If you have already been denied and your coverage comes through an employer, federal ERISA claims rules go further: when a plan relies on an internal rule, guideline, or protocol to deny a claim, it must either give you that rule or tell you a copy will be provided free of charge on request (29 CFR 2560.503-1). Ask for it by name. A denial letter that just says "not medically necessary" is not the criterion — it's the conclusion.
2. Ask the prescriber's office who does PAs — and what they're sending
Most practices have a specific person or team (a PA coordinator, medication-access nurse, or a service the practice pays for). Ask for that person by name, then ask two concrete questions: which criteria are you documenting against, and which visit notes are you attaching? A submission that lists your BMI but never mentions your hypertension diagnosis or the six months you spent with a dietitian gets denied on paper even when you qualify in reality.
3. Bring your own records
Your history of weight-management attempts is evidence, and it is usually sitting in places the practice can't see: an old commercial weight-program account, gym or app history, a nutritionist's invoices, prior prescriptions (including metformin, if it was used for weight or insulin resistance), old weights from other clinics. Hand it over. Ask that it be summarized in the chart note, because attachments the reviewer doesn't read do nothing.
What a strong submission actually contains
The reviewer is working through a checklist, so the packet should read like one. In practice that is four things on the page: a dated height and weight with the calculated BMI; the coded weight-related diagnoses with the evidence behind them (an A1c, a lipid panel, a blood-pressure series, a sleep-study report); a dated account of the lifestyle program that was tried — what it consisted of, how long it ran, what the weight did; and, where step therapy applies, the fill history or the documented reason the preferred agent is not appropriate for you. Every element should trace back to a note in the chart rather than an assertion in a cover letter.
The line we will not help you cross
Never misstate your history to an insurer, and never ask a clinician to write something into your chart that isn't true — not a symptom you don't have, not a diagnosis you weren't given, not a diet program you didn't do. Beyond being dishonest, it gives the plan grounds to rescind coverage and claw back what it paid, and it puts your prescriber's licence on the line. There is a real difference between documenting what is true and currently undocumented (right, and often decisive) and manufacturing what is not true (wrong, and fragile).
If you are denied
You are in ordinary company. KFF's analysis of federal transparency data found that HealthCare.gov insurers denied about 19% of in-network claims in 2024, that consumers appealed fewer than 1% of those denials, and that where an appeal was filed, insurers upheld their own decision 66% of the time — meaning roughly a third of appealed denials were overturned on internal review alone. The appeal is the underused tool.
For non-grandfathered plans, HealthCare.gov's rules give you 180 days to file an internal appeal; the plan must decide within 30 days when the service hasn't happened yet (a pending prescription counts), and within 72 hours for an expedited urgent appeal. If the internal appeal fails, you can request an independent external review by a reviewer who does not work for the insurer.
Practical order of operations: get the exact denial reason in writing → get the criterion it was measured against → have the prescriber supply the specific missing element (a code, a note, a date) → ask for a peer-to-peer review, where your prescriber speaks to the plan's reviewing clinician. A large share of "denials" are documentation gaps wearing a medical-necessity costume. The mechanics of the appeal itself — deadlines, the letter of medical necessity, external review — are in our guide to appealing a GLP-1 insurance denial.
If your plan simply excludes weight-loss drugs
Then there is no criterion to meet, and no appeal on medical necessity will win — the drug isn't covered for that use at all. That is worth confirming explicitly, because it changes what you do next. Employers pick that exclusion, so the conversation that could actually change it is with your benefits team, not the plan's appeals unit.
| Route | Listed price | Conditions to read carefully |
|---|---|---|
| NovoCare Pharmacy (Wegovy, semaglutide) | Novo lists self-pay at about $299/month for the injection pen and $149/month for the tablet. | Prices are dose-specific and the offers are time-limited — Novo lists the 4 mg tablet at $149/month only through August 31, 2026, then $199/month. The page is updated frequently; read your own dose's line before assuming. |
| LillyDirect (Zepbound, tirzepatide) | $299/month at 2.5 mg, $399/month at 5 mg, $449/month at 7.5–15 mg. | A "month" is 28 days. The $449 tier requires refilling within 45 days of your previous delivery; miss the window and Lilly's published regular price applies — $499/month at 7.5 mg and $699/month at 10, 12.5 and 15 mg. |
| Medicare GLP-1 Bridge (CMS demonstration) | $50/month copay. | Runs July 1, 2026 – December 31, 2027, covering Wegovy (injection and tablets), the Zepbound KwikPen and Foundayo when used to reduce and maintain body weight. Prior authorization goes through a single central CMS processor. The Part D deductible doesn't apply, and the $50 doesn't count toward your true out-of-pocket total. |
Neither cash route is cheap, and neither is a recommendation — they are the honest arithmetic against which a denial should be judged. Our cost and coverage estimator walks through the same math with your numbers.
Disclosure: VidaBeacon may earn a commission if you book care or buy a product through some links on this site. It never changes what we write, and we do not accept payment for a recommendation.
A note on dose, because plans ask about it
PA forms often ask which dose is being requested, and re-authorizations sometimes hinge on it. The FDA labels publish a titration schedule — starting low and stepping up at intervals — and that schedule is public fact you're allowed to read (see the GLP-1 dosing schedule and semaglutide). It is a reference, not an instruction: your prescriber sets your dose. Do not self-adjust, do not stretch or split doses to make a supply last, and do not double up after a missed dose. If cost is pushing you toward any of that, say so to your prescriber — it is a coverage problem, and it has coverage answers.
Talk to your prescriber if…
- You were denied and don't know the exact stated reason — ask them to pull the denial and request a peer-to-peer review.
- Your chart may be missing something true: an existing sleep apnea, hypertension or dyslipidemia diagnosis, a prediabetic A1c, a documented dietitian program.
- You are rationing doses, skipping fills, or considering stopping because of cost. Stopping or restarting a GLP-1 is a clinical decision, not a budgeting one — bring the budget problem to the visit.
- You are considering a compounded version, or an online prescriber you found through an ad. Compounded GLP-1s are not FDA-approved products — the FDA does not review them for safety, effectiveness or quality — and plans do not cover them, so a compounded prescription is a cash purchase, not a PA question. Ask who the prescribing clinician is, whether they are licensed in your state, what pharmacy dispenses, whether they will do the PA for you, and what happens if you're denied. Our guide to evaluating online GLP-1 care lays out the questions; we don't name a winner, because there isn't one for everyone.
- You have symptoms that worry you — persistent vomiting, severe abdominal pain, signs of dehydration — which is a clinical call, not a coverage one.
The most useful sentence in this whole article is the one you say on the phone: "Send me the coverage criteria." Everything else follows from having the document that the decision is actually made with. More on the broader picture in weight and metabolism.
